The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy

Georg Holgersson; Martin Sandelin; Even Hoye; Stefan Bergstrom; Roger Henriksson; Simon Ekman; Jan Nyman; Martin Helsing; Signe Friesland; Ola Brodin; Margareta Holgersson; Kristina Lamberg Lundstrom; Christer Janson; Lars Ekberg; Charlotte Morth; Thomas Blystad; Sven-Börje Ewers; Britta Loden; Michael Bergqvist

The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy

Georg Holgersson, Martin Sandelin, Even Hoye, Stefan Bergstrom, Roger Henriksson, Simon Ekman, Jan Nyman, Martin Helsing, Signe Friesland, Ola Brodin, Margareta Holgersson, Kristina Lamberg Lundstrom, Christer Janson, Lars Ekberg, Charlotte Morth, Thomas Blystad, Sven-Börje Ewers, Britta Loden, Michael Bergqvist

Breastcancer-genetics

Research output: Contribution to journal › Article › peer-review

1 Citation (SciVal)

Abstract

Aim: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and Methods: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (>= 50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts. Results: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75). Conclusion: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.

Original language	English
Pages (from-to)	1339-1346
Journal	Anticancer research
Volume	32
Issue number	4
Publication status	Published - 2012

Subject classification (UKÄ)

Cancer and Oncology

Keywords

NSCLC
lung cancer
radiotherapy
predictive value
age

Cite this

Holgersson, G., Sandelin, M., Hoye, E., Bergstrom, S., Henriksson, R., Ekman, S., Nyman, J., Helsing, M., Friesland, S., Brodin, O., Holgersson, M., Lundstrom, K. L., Janson, C., Ekberg, L., Morth, C., Blystad, T., Ewers, S-B., Loden, B., & Bergqvist, M. (2012). The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy. Anticancer research, 32(4), 1339-1346.

Holgersson, Georg ; Sandelin, Martin ; Hoye, Even ; Bergstrom, Stefan ; Henriksson, Roger ; Ekman, Simon ; Nyman, Jan ; Helsing, Martin ; Friesland, Signe ; Brodin, Ola ; Holgersson, Margareta ; Lundstrom, Kristina Lamberg ; Janson, Christer ; Ekberg, Lars ; Morth, Charlotte ; Blystad, Thomas ; Ewers, Sven-Börje ; Loden, Britta ; Bergqvist, Michael. / The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy. In: Anticancer research. 2012 ; Vol. 32, No. 4. pp. 1339-1346.

@article{7040a41944514e218ae0d1b2d04c4928,

title = "The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy",

abstract = "Aim: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and Methods: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (>= 50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts. Results: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75). Conclusion: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.",

keywords = "NSCLC, lung cancer, radiotherapy, predictive value, age",

author = "Georg Holgersson and Martin Sandelin and Even Hoye and Stefan Bergstrom and Roger Henriksson and Simon Ekman and Jan Nyman and Martin Helsing and Signe Friesland and Ola Brodin and Margareta Holgersson and Lundstrom, {Kristina Lamberg} and Christer Janson and Lars Ekberg and Charlotte Morth and Thomas Blystad and Sven-B{\"o}rje Ewers and Britta Loden and Michael Bergqvist",

year = "2012",

language = "English",

volume = "32",

pages = "1339--1346",

journal = "Anticancer research",

issn = "1791-7530",

publisher = "International Institute of Cancer Research",

number = "4",

}

Holgersson, G, Sandelin, M, Hoye, E, Bergstrom, S, Henriksson, R, Ekman, S, Nyman, J, Helsing, M, Friesland, S, Brodin, O, Holgersson, M, Lundstrom, KL, Janson, C, Ekberg, L, Morth, C, Blystad, T, Ewers, S-B, Loden, B & Bergqvist, M 2012, 'The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy', Anticancer research, vol. 32, no. 4, pp. 1339-1346.

The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy. / Holgersson, Georg; Sandelin, Martin; Hoye, Even; Bergstrom, Stefan; Henriksson, Roger; Ekman, Simon; Nyman, Jan; Helsing, Martin; Friesland, Signe; Brodin, Ola; Holgersson, Margareta; Lundstrom, Kristina Lamberg; Janson, Christer; Ekberg, Lars; Morth, Charlotte; Blystad, Thomas; Ewers, Sven-Börje; Loden, Britta; Bergqvist, Michael.

In: Anticancer research, Vol. 32, No. 4, 2012, p. 1339-1346.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy

AU - Holgersson, Georg

AU - Sandelin, Martin

AU - Hoye, Even

AU - Bergstrom, Stefan

AU - Henriksson, Roger

AU - Ekman, Simon

AU - Nyman, Jan

AU - Helsing, Martin

AU - Friesland, Signe

AU - Brodin, Ola

AU - Holgersson, Margareta

AU - Lundstrom, Kristina Lamberg

AU - Janson, Christer

AU - Ekberg, Lars

AU - Morth, Charlotte

AU - Blystad, Thomas

AU - Ewers, Sven-Börje

AU - Loden, Britta

AU - Bergqvist, Michael

PY - 2012

Y1 - 2012

N2 - Aim: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and Methods: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (>= 50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts. Results: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75). Conclusion: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.

AB - Aim: The aim of the present study was to retrospectively investigate the impact of induction chemotherapy on treatment outcome in patients treated with curatively intended radiotherapy for non-small cell lung cancer (NSCLC). Patients and Methods: Patients with a diagnosed NSCLC that have been subjected to curatively intended irradiation (>= 50 Gy) and treated in an oncology department in Sweden during the years 1990-2000 were included in the study. Operated patients and patients having received concomitant chemotherapy were excluded. The included patients were localised by a manual search of all the oncology departments' medical records and radiation charts. Results: Patients treated with induction chemotherapy (n=79) had a significantly better overall survival compared with patients treated with radiotherapy alone (p=0.0097) in a univariate Cox regression analysis. A platinum/taxane combination produced the greatest survival benefit; hazard ratio=0.49 (95% confidence interval=0.31 to 0.75). Conclusion: We found that patients treated with induction chemotherapy in addition to radiotherapy for NSCLC have a better overall survival than patients treated with radiotherapy alone and that the best results are achieved using a platinum/taxane combination.

KW - NSCLC

KW - lung cancer

KW - radiotherapy

KW - predictive value

KW - age

M3 - Article

VL - 32

SP - 1339

EP - 1346

JO - Anticancer research

JF - Anticancer research

SN - 1791-7530

IS - 4

ER -

The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy

Abstract

Subject classification (UKÄ)

Keywords

Fingerprint

Cite this